These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series. Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O; Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575 [TBL] [Abstract][Full Text] [Related]
8. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ Front Neurol; 2023; 14():1114667. PubMed ID: 36873431 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL; Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of neuromyelitis optica spectrum disorders. Romeo AR Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809 [TBL] [Abstract][Full Text] [Related]
12. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. Gao Y; Zhang B; Yang J Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095 [TBL] [Abstract][Full Text] [Related]
14. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder]. Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559 [TBL] [Abstract][Full Text] [Related]
15. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX Front Immunol; 2023; 14():1257955. PubMed ID: 37915570 [TBL] [Abstract][Full Text] [Related]
16. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202 [TBL] [Abstract][Full Text] [Related]
17. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Duchow A; Bellmann-Strobl J Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776 [TBL] [Abstract][Full Text] [Related]
18. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders. Paton DM Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218 [TBL] [Abstract][Full Text] [Related]
19. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC; Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]